The study found that AstraZeneca’s anti‑PD‑L1 antibody durvalumab (Imfinzi) plus the anti‑CTLA‑4 antibody tremelimumab (Imjudo), administered alongside lenvatinib and TACE, significantly prolonged progression‑free survival (PFS) compared with TACE alone. The improvement met the trial’s primary endpoint and was described as both statistically robust and clinically relevant.

At the time of the interim analysis, overall survival (OS)—a key secondary endpoint—also trended in favor of the combination regimen, although formal statistical testing for OS has not yet been completed. Follow‑up for survival and other secondary outcomes is ongoing.

Building on the STRIDE Regimen

Patients in the investigational arms received treatment based on the STRIDE regimen, which consists of a single priming dose of tremelimumab plus regular‑interval durvalumab. In EMERALD‑3, STRIDE was delivered before and during TACE, either with or without the multikinase inhibitor lenvatinib.

Notably, the arm evaluating STRIDE plus TACE (without lenvatinib) also showed encouraging signals for both PFS and OS versus TACE alone, although these comparisons were not formally powered for statistical significance at this stage.

The findings suggest that introducing systemic immunotherapy earlier in the disease course—rather than reserving it for advanced or post‑embolization settings—may help delay progression and recurrence, a persistent challenge in embolization‑eligible HCC.

Addressing an Area of High Unmet Need

HCC is the most common form of liver cancer and remains a leading cause of cancer mortality worldwide. For patients with unresectable disease who are eligible for embolization procedures, TACE is a long‑standing standard of care. However, disease control is often short‑lived, with many patients experiencing progression or relapse within months.

More than 200,000 patients globally are expected to be eligible for embolization by 2026, underscoring the need for strategies that can improve durability of response in this population.

Commenting on the results, principal investigator Ghassan Abou‑Alfa, MD, of Memorial Sloan Kettering Cancer Center, noted that dual immunotherapy provides a new systemic option for patients who previously lacked effective treatments to prevent disease worsening after TACE. He highlighted EMERALD‑3 as evidence that combining STRIDE with lenvatinib and locoregional therapy can meaningfully reduce the risk of progression while showing encouraging survival trends.

Consistent Safety Profile

According to the interim analysis, the safety findings were in line with the known adverse‑event profiles of the individual agents. No new safety concerns were identified with the multi‑modality approach, supporting its feasibility in this setting.

Trial Design and Next Steps

EMERALD‑3 is a global, randomized, open‑label, sponsor‑blinded phase III trial involving 760 patients across 171 centers in 22 countries. Participants were assigned to one of three arms: TACE alone, TACE plus STRIDE, or TACE plus STRIDE and lenvatinib. The primary endpoint was PFS for the quadruple‑combination arm versus TACE alone, while secondary endpoints include OS and outcomes for the STRIDE‑only combination.

AstraZeneca reported that the data will be presented at an upcoming scientific meeting and are being reviewed with regulatory authorities worldwide.

Broader Implications

These results build on earlier evidence from the HIMALAYA trial, which established the STRIDE regimen as an effective option in advanced, unresectable HCC. By demonstrating benefit in an earlier disease stage, EMERALD‑3 supports a shift toward integrating immunotherapy with locoregional treatments to improve long‑term outcomes in liver cancer.

If confirmed with longer follow‑up, this approach could represent a new therapeutic paradigm for patients with embolization‑eligible HCC, an area where durable disease control has remained elusive.